Objective: The paper analyzes the influence of centralized procurement policy on drug procurement in the agreed procurement cycle and renewal period of public medical institutions at different levels. Methods: The changes of drug purchase volume, purchase expenditure and average daily cost of public medical institutions at different levels in 7 pilot cities were analyzed by interrupted time series analysis. Results: The purchase volume of centralized drug varieties increased by 15.36% and 4.61% in the pilot period and the renewal period, respectively. The growth rate of the purchase volume of alternative drug varieties in the pilot period and the renewal period was higher than that of centralize drug varieties, which was 17.30% and 5.60%, respectively. In the base period, the procurement volume of original drugs, reviewed generic drugs and unreviewed generic drugs accounted for 27.07%, 53.00% and 19.93%, respectively. The proportion of reviewed generic drugs in the pilot period and the renewal period increased by 34.71% and 0.92%, respectively. In the base period, the purchase volume of original drugs, reviewed generic drugs and unreviewed generic drugs accounted for 40.46%, 42.87% and 16.68%, respectively, while the proportion of reviewed generic drugs in the pilot period and the renewal period increased by 20.07% and 0.07%, respectively. Conclusion: The policy effect of primary medical institutions is behind schedule. The reviewed generic drug substitution effect of the centralized drug varieties was obvious, and the drug quality of primary medical institutions was improved. The DDDc of unreviewed generic drugs in the renewal period of Level-3 and Level-2 medical institutions increased abnormally.
Key words
national centralized drug procurement /
procurement volume /
procurement expenditure
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
[1] 王煜昊,徐伟,路娜娜,等.“4+7”集中带量采购实施效果分析——基于9试点地区药品销售数据[J]. 中国卫生政策研究, 2021, 14(02): 36-43.
[2] 谢金平,王斌,陈缪丰,等.常州市第二批国家药品集中采购政策实施效果研究——基于双组间断时间序列分析[J].中国卫生政策研究,2022,15(05):59-66.
[3] 谢金平,胡紫馨,王苑如,等. 国家药品集中采购政策对四直辖市药品价格、费用及仿制药替代的影响分析[J].中国卫生经济, 2021, 40(09): 24-28.
[4] 林燕铭,周娜,韩汶静,等. 药品集中带量采购政策对药品利用与支出的影响分析[J].中国卫生经济, 2022, 41(09): 13-18.
[5] YING YANG, HU RUNHU, GENG XIN, et al.The impact of National Centralised Drug Procurement policy on the use of policy-related original and generic drugs in China[J]. International Journal of Health Planning and Management, 2022, 37(3): 1650-1662.
[6] JING YUAN, LU Z-KEVIN, XIONG XIAOMO, et al.Impact of National Volume-Based Procurement on the Procurement Volumes and Spending for Antiviral Medications of Hepatitis B Virus[J]. Frontiers in Pharmacology, 2022, 1384-2944.
[7] JIANCHENG LU, LONG HONGFEI, SHEN YUAN, et al.The change of drug utilization in China's public healthcare institutions under the "4+7" centralized drug procurement policy: Evidence from a natural experiment in China[J]. Frontiers in Pharmacology, 2022, 13.
[8] XIAOTONG WEN, YIN SHICHENG, CUI LANYUE, et al.The Effects of the National Centralized Drug Purchasing Pilot Program on Nucleos(t)ide Analogs in Shenzhen City: An Interrupted Time Series Analysis[J]. Frontiers in Public Health, 2021, 9.
[9] XIAOTONG WEN, WANG ZHAOLUN, XU LUXINYI, et al.The impacts of the "4+7" pilot policy on the volume, expenditures, and daily cost of Serotonin-Specific Reuptake Inhibitors (SSRIs) antidepressants: A quasi-experimental study[J]. Frontiers in Pharmacology, 2022, 13.
[10] YING YANG, TONG RUIWEN, YIN SHICHENG, et al.The impact of “4 + 7” volume-based drug procurement on the volume, expenditures, and daily costs of antihypertensive drugs in Shenzhen, China: an interrupted time series analysis[J]. BMC Health Services Research, 2021, 21(1).
[11] 徐赟. 药品集中采购的政策协同度评价及其优化策略研究[D].南京中医药大学, 2022.
[12] 陈缪丰,谢金平,王斌,等.常州市各级医院带量采购政策实施效果差异研究[J].中国卫生资源, 2022, 25(06): 765-769.
